Genomsekvensering for persontilpasset kreftbehandling

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 21, 2012, Pages 2406-2408

  Skotheim, Rolf I ^a   Meza Zepeda, Leonardo A ^b   Hovig, Eivind ^b   Lønning, Per E ^c,d   Lothe, Ragnhild A ^a   Myklebost, Ola ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; GENOMICS; HUMAN; HUMAN GENOME; MUTATION; NEOPLASM; NOTE; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; TUMOR GENE;

DNA MUTATIONAL ANALYSIS; GENES, NEOPLASM; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS;

EID: 84871963903     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.12.0784     Document Type: Note

References (19)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-24.
3. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.
4. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
5. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
6. Buchdunger E, Cioffi CL, Law N et al. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and plateletderived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
7. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007; 448: 561-6.
8. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
9. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
10. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
11. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
12. Thomas RK, Baker AC, Debiasi RM et al. Highthroughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-51.
13. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
14. Snuderl M, Fazlollahi L, Le LP et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-7.
15. Pritchard CC, Smith C, Salipante SJ et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012; 14: 357-66.
16. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18: 382-4.
17. Harismendy O, Schwab RB, Bao L et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol 2011; 12: R124.
18. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra121.
19. Norwegian Cancer Genomics Consortium (NCGC). www.cancergenomics.no (3.9.2012).